9-104812587-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_005502.4(ABCA1):c.4037G>A(p.Gly1346Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000589 in 1,614,060 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000058 ( 0 hom. )
Consequence
ABCA1
NM_005502.4 missense
NM_005502.4 missense
Scores
11
7
1
Clinical Significance
Conservation
PhyloP100: 7.54
Genes affected
ABCA1 (HGNC:29): (ATP binding cassette subfamily A member 1) The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intracellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the ABC1 subfamily. Members of the ABC1 subfamily comprise the only major ABC subfamily found exclusively in multicellular eukaryotes. With cholesterol as its substrate, this protein functions as a cholesteral efflux pump in the cellular lipid removal pathway. Mutations in both alleles of this gene cause Tangier disease and familial high-density lipoprotein (HDL) deficiency. [provided by RefSeq, Sep 2019]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABCA1 | NM_005502.4 | c.4037G>A | p.Gly1346Glu | missense_variant | 28/50 | ENST00000374736.8 | NP_005493.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABCA1 | ENST00000374736.8 | c.4037G>A | p.Gly1346Glu | missense_variant | 28/50 | 1 | NM_005502.4 | ENSP00000363868 | P1 | |
ABCA1 | ENST00000678995.1 | c.4043G>A | p.Gly1348Glu | missense_variant | 28/50 | ENSP00000504612 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152180Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
10
AN:
152180
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000115 AC: 29AN: 251466Hom.: 0 AF XY: 0.000110 AC XY: 15AN XY: 135906
GnomAD3 exomes
AF:
AC:
29
AN:
251466
Hom.:
AF XY:
AC XY:
15
AN XY:
135906
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000581 AC: 85AN: 1461880Hom.: 0 Cov.: 32 AF XY: 0.0000564 AC XY: 41AN XY: 727240
GnomAD4 exome
AF:
AC:
85
AN:
1461880
Hom.:
Cov.:
32
AF XY:
AC XY:
41
AN XY:
727240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152180Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74344
GnomAD4 genome
AF:
AC:
10
AN:
152180
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74344
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
12
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:2Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 19, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 17, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Dec 12, 2019 | Reported as likely pathogenic by another clinical laboratory in ClinVar but additional evidence is not available (ClinVar Variant ID#521460; Landrum et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 30333156, 32041611, 31589614) - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 12, 2016 | - - |
Tangier disease;C5231558:Hypoalphalipoproteinemia, primary, 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Nov 16, 2022 | The c.4037G>A variant has previously been reported as a variant of uncertain significance in a study performed on a cohort of dyslipidemia patients [PMID:32041611]. However, the disease phenotype and the number of affected individuals with this variant have not been specified in the study [PMID:32041611]. This variant has also been reported as a compound heterozygous or heterozygous state in individuals with HDL deficiency [PMID: 30333156, 35460704]. This variant has been deposited in ClinVar [ClinVar ID: 521460] as Likely Pathogenic, Variant of Uncertain Significance, and Likely Benign. The c.4037G>A variant is observed in 58 alleles (0.0098%minor allele frequency with 0 homozygotes) in population databases (gnomAD v2.1.1 and v3.1.2, TOPMed Freeze 8) suggesting it is not a common benign variant in the populations represented in those databases. The c.4037G>A variant is located in exon 28 of this 50-exon gene and is predicted to replace an evolutionarily conserved glycine amino acid with glutamic acid at position 1346 in the intracellular helices 3 of the encoded protein [PMID: 35460704]. In silico predictions are in favor of damaging effect for p.(Gly1346Glu) the variant [(CADD v1.6 = 27.9, REVEL = 0.833)]; however, there are no functional studies to support or refute these predictions. Based on available evidence this c.4037G>A p.(Gly1346Glu) variant identified in ABCA1 is classified as a Variant of UncertainSignificance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M
MutationTaster
Benign
D
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MutPred
Loss of MoRF binding (P = 0.043);
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at